Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

261 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Small Molecule-Based Enzyme Inhibitors in the Treatment of Primary Hyperoxalurias.
Moya-Garzon MD, Gomez-Vidal JA, Alejo-Armijo A, Altarejos J, Rodriguez-Madoz JR, Fernandes MX, Salido E, Salido S, Diaz-Gavilan M. Moya-Garzon MD, et al. Among authors: salido s, salido e. J Pers Med. 2021 Jan 27;11(2):74. doi: 10.3390/jpm11020074. J Pers Med. 2021. PMID: 33513899 Free PMC article. Review.
New salicylic acid derivatives, double inhibitors of glycolate oxidase and lactate dehydrogenase, as effective agents decreasing oxalate production.
Moya-Garzon MD, Rodriguez-Rodriguez B, Martin-Higueras C, Franco-Montalban F, Fernandes MX, Gomez-Vidal JA, Pey AL, Salido E, Diaz-Gavilan M. Moya-Garzon MD, et al. Among authors: salido e. Eur J Med Chem. 2022 Jul 5;237:114396. doi: 10.1016/j.ejmech.2022.114396. Epub 2022 Apr 25. Eur J Med Chem. 2022. PMID: 35500475 Free article.
In vivo CRISPR-Cas9 inhibition of hepatic LDH as treatment of primary hyperoxaluria.
Martinez-Turrillas R, Martin-Mallo A, Rodriguez-Diaz S, Zapata-Linares N, Rodriguez-Marquez P, San Martin-Uriz P, Vilas-Zornoza A, Calleja-Cervantes ME, Salido E, Prosper F, Rodriguez-Madoz JR. Martinez-Turrillas R, et al. Among authors: salido e. Mol Ther Methods Clin Dev. 2022 Mar 16;25:137-146. doi: 10.1016/j.omtm.2022.03.006. eCollection 2022 Jun 9. Mol Ther Methods Clin Dev. 2022. PMID: 35402636 Free PMC article.
CRISPR/Cas9-mediated glycolate oxidase disruption is an efficacious and safe treatment for primary hyperoxaluria type I.
Zabaleta N, Barberia M, Martin-Higueras C, Zapata-Linares N, Betancor I, Rodriguez S, Martinez-Turrillas R, Torella L, Vales A, Olagüe C, Vilas-Zornoza A, Castro-Labrador L, Lara-Astiaso D, Prosper F, Salido E, Gonzalez-Aseguinolaza G, Rodriguez-Madoz JR. Zabaleta N, et al. Among authors: salido e. Nat Commun. 2018 Dec 21;9(1):5454. doi: 10.1038/s41467-018-07827-1. Nat Commun. 2018. PMID: 30575740 Free PMC article.
Generation of an induced pluripotent stem cell line (CIMAi001-A) from a compound heterozygous Primary Hyperoxaluria Type I (PH1) patient carrying p.G170R and p.R122* mutations in the AGXT gene.
Martinez-Turrillas R, Rodriguez-Diaz S, Rodriguez-Marquez P, Martin-Mallo A, Salido E, Beck BB, Prosper F, Rodriguez-Madoz JR. Martinez-Turrillas R, et al. Among authors: salido e. Stem Cell Res. 2019 Dec;41:101626. doi: 10.1016/j.scr.2019.101626. Epub 2019 Oct 18. Stem Cell Res. 2019. PMID: 31715429 Free article.
261 results